Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.

Abstract: Provided herein are hydrogel-hydrocolloid sealant compositions for use as soft-tissue sealants. The compositions can include a cross-linkable electrophilic component; a cross-linkable nucleophilic component; a swellable filler material including gelatin; and, a buffer having a pH in the range of about 9.0 to about 10.0. The compositions can have a first fluid state and a second crosslinked state, and in the crosslinked state, the electrophilic and nucleophilic components can crosslink to form a crosslinked hydrogel network where the swellable filler material including gelatin is disposed within the crosslinked network. Also provided are systems and methods of manufacturing the sealant compositions as well as methods of repairing soft tissue defects including applying the sealant compositions disclosed herein.

Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Abstract: A method of making a biocompatible composition for sealing tissue includes mixing a first fluid having a first reactive component (e.g., an electrophile) and a second fluid having a second reactive component (e.g., a nucleophile) to form a mixture and expressing the mixture. During expression, a pH modifying fluid (e.g., NaOH) is added to the mixture at a rate that changes. In one embodiment, a higher ratio of the pH modifying fluid is added to the mixture during a first expressing stage and a lower ratio of said pH modifying fluid is added to the mixture during a second expressing stage. During the first expressing stage, a mixing ratio of the pH modifying fluid, the first fluid and the second fluid is 0.7-1.4:1:1. During the second expressing stage, the mixing ratio of the pH modifying fluid, the first fluid and the second fluid is 0.12-0.24:1:1.

Abstract: A method of sealing a resected surface of an organ includes applying a synthetic matrix to a resected surface of an organ, and applying an adhesive on the synthetic matrix so that the adhesive penetrates through interstices of the synthetic matrix for contacting an interface between the synthetic matrix and the resected surface of the organ. The method includes curing the adhesive for bonding the synthetic matrix to the resected surface of the organ. The synthetic matrix is a non-woven mesh made of polyglactin 910 or any other synthetic or non-synthetic fabric having a similar porosity or density. The adhesive is a biosynthetic or a synthetic adhesive. After penetrating through the pores of the synthetic matrix and curing, the cured biosynthetic or synthetic adhesive mechanically interlocks with the synthetic matrix for adhering the synthetic matrix to the tissue for creating a sealing barrier.

Abstract: The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.

Abstract: A method and kit for stopping cerebrospinal fluid (CSF) leaks, comprising penetrating and passing through a dural tissue an applicator to access an interior dural space, injecting from the applicator a fibrinogen-containing solution into said dural space, applying a sealing member containing a fibrinogen polymerizing agent onto an exterior surface of the dural tissue, and forming a polymerized fibrinogen or polymerized fibrin clot by contacting the injected fibrinogen-containing solution and the fibrinogen polymerizing agent.

Abstract: The present invention provides a tissue sealing plug comprising a substrate comprising foamed gelatin impregnated with polyethylene glycol that is liquid at room temperature, wherein the weight ratio of polyethylene glycol to foamed gelatin in the substrate is about 4:1 to about 6.8:1 and the substrate is substantially free of air, along with methods of using the plug for closing tissue punctures in the lung.

Abstract: The present invention provides a kit for preparing a composition for sealing a lung tract, comprising: (a) a first component comprising: (i) a fibrinogen solution, and (ii) prewet gelatin particles in an aqueous solution; and (b) a second component comprising: (i) a thrombin solution, and (ii) a dry gelatin powder; wherein the first and second components are stored separately and configured for mixing together to form a composition that is flowable and cross-linkable. The composition may be used to seal tissue tracts such as lung tissue tracts.

Abstract: Disclosed are devices for detection of bleeding during surgical procedures and uses thereof. Also disclosed are methods of localizing a bleeding site during surgical procedures, and methods for evaluating an intensity of bleeding during the surgical procedures. The detection of bleeding is based, inter alia, on the presence of thrombin activity in a bleeding site.

Abstract: The present invention is directed to hemostatic sealants having a compressed porous substrate, an electrophilic group containing component that is not gelatin or collagen, a nucleophilic group containing component, and a buffering agent. The present invention also relates to method for manufacture and use of such sealants to seal and/or achieve hemostasis.

Abstract: A method and kit for stopping cerebrospinal fluid (CSF) leaks, comprising penetrating and passing through a dural tissue an applicator to access an interior dural space, injecting from the applicator a fibrinogen-containing solution into said dural space, applying a sealing member containing a fibrinogen polymerizing agent onto an exterior surface of the dural tissue, and forming a polymerized fibrinogen or polymerized fibrin clot by contacting the injected fibrinogen-containing solution and the fibrinogen polymerizing agent.

Abstract: The present invention is directed to dry lyophilized foam plugs that are a polymeric reaction product of at least a pair of co-reactive polyethylene glycol having reactive moieties in which substantially all of reactive moieties have reacted prior to lyophilization or blend of biomaterial and a reactive polyethylene glycol or plasma derived biomaterial reaction product and wherein the plug has an overall pore void content of about 30-45%, and a microporous structure with an average pore generally between 20 and 95 ?m.

Abstract: The invention relates to syringes for storing and mixing components.

Abstract: A method of sealing a resected surface of an organ includes applying a synthetic matrix to a resected surface of an organ, and applying an adhesive on the synthetic matrix so that the adhesive penetrates through interstices of the synthetic matrix for contacting an interface between the synthetic matrix and the resected surface of the organ. The method includes curing the adhesive for bonding the synthetic matrix to the resected surface of the organ. The synthetic matrix is a non-woven mesh made of polyglactin 910 or any other synthetic or non-synthetic fabric having a similar porosity or density. The adhesive is a biosynthetic or a synthetic adhesive. After penetrating through the pores of the synthetic matrix and curing, the cured biosynthetic or synthetic adhesive mechanically interlocks with the synthetic matrix for adhering the synthetic matrix to the tissue for creating a sealing barrier.

Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Abstract: Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.

Abstract: The present invention is directed to hemostatic sealants having a compressed porous substrate, an electrophilic group containing component that is not gelatin or collagen, a nucleophilic group containing component, and a buffering agent. The present invention also relates to method for manufacture and use of such sealants to seal and/or achieve hemostasis.

Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.